These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 23749293

  • 21. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
    Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neill GN, BG-12 Phase IIb Study Investigators.
    Lancet; 2008 Oct 25; 372(9648):1463-72. PubMed ID: 18970976
    [Abstract] [Full Text] [Related]

  • 22. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.
    Gold R, Arnold DL, Bar-Or A, Hutchinson M, Kappos L, Havrdova E, MacManus DG, Yousry TA, Pozzilli C, Selmaj K, Sweetser MT, Zhang R, Yang M, Potts J, Novas M, Miller DH, Kurukulasuriya NC, Fox RJ, Phillips TJ.
    Mult Scler; 2017 Feb 25; 23(2):253-265. PubMed ID: 27207449
    [Abstract] [Full Text] [Related]

  • 23. Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis.
    Burness CB, Deeks ED.
    CNS Drugs; 2014 Apr 25; 28(4):373-87. PubMed ID: 24623127
    [Abstract] [Full Text] [Related]

  • 24. BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety.
    Fox RJ, Kita M, Cohan SL, Henson LJ, Zambrano J, Scannevin RH, O'Gorman J, Novas M, Dawson KT, Phillips JT.
    Curr Med Res Opin; 2014 Feb 25; 30(2):251-62. PubMed ID: 24131282
    [Abstract] [Full Text] [Related]

  • 25. Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study.
    Kappos L, Gold R, Miller DH, MacManus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Eraksoy M, Meluzinova E, Dufek M, Yang M, Dawson K, O'Neill GN.
    Mult Scler; 2012 Mar 25; 18(3):314-21. PubMed ID: 21878455
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J, Fay M, Iyer R, Sarda S, Livingston T.
    J Med Econ; 2016 Mar 25; 19(4):432-42. PubMed ID: 26707273
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
    Comi G, Filippi M, Wolinsky JS.
    Ann Neurol; 2001 Mar 25; 49(3):290-7. PubMed ID: 11261502
    [Abstract] [Full Text] [Related]

  • 30. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.
    Simpson D, Noble S, Perry C.
    CNS Drugs; 2002 Mar 25; 16(12):825-50. PubMed ID: 12421116
    [Abstract] [Full Text] [Related]

  • 31. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
    Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L, FREEDOMS study group.
    Lancet Neurol; 2012 May 25; 11(5):420-8. PubMed ID: 22494956
    [Abstract] [Full Text] [Related]

  • 32. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis.
    Rose JW, Giovannoni G, Wiendl H, Gold R, Havrdová E, Kappos L, Selmaj KW, Zhao J, Riester K, Tsao LC, Greenberg SJ.
    Mult Scler Relat Disord; 2017 Oct 25; 17():32-40. PubMed ID: 29055471
    [Abstract] [Full Text] [Related]

  • 33. Dimethyl Fumarate: A Review in Relapsing-Remitting MS.
    Deeks ED.
    Drugs; 2016 Feb 25; 76(2):243-54. PubMed ID: 26689201
    [Abstract] [Full Text] [Related]

  • 34. Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis.
    Simpson D, Noble S, Perry C.
    BioDrugs; 2003 Feb 25; 17(3):207-10. PubMed ID: 12749757
    [Abstract] [Full Text] [Related]

  • 35. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
    Hennessy B, Zierhut ML, Kracker H, Keenan A, Sidorenko T.
    Mult Scler Relat Disord; 2022 Aug 25; 64():103908. PubMed ID: 35803162
    [Abstract] [Full Text] [Related]

  • 36. Diroximel Fumarate in Relapsing Forms of Multiple Sclerosis: A Profile of Its Use.
    Paik J.
    CNS Drugs; 2021 Jun 25; 35(6):691-700. PubMed ID: 34057708
    [Abstract] [Full Text] [Related]

  • 37. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
    Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L, RADIANCE Trial Investigators.
    Lancet Neurol; 2019 Nov 25; 18(11):1021-1033. PubMed ID: 31492652
    [Abstract] [Full Text] [Related]

  • 38. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
    Thomas RH, Wakefield RA.
    Am J Health Syst Pharm; 2015 Jan 01; 72(1):25-38. PubMed ID: 25511835
    [Abstract] [Full Text] [Related]

  • 39. Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.
    Harrison DM, Gladstone DE, Hammond E, Cheng J, Jones RJ, Brodsky RA, Kerr D, McArthur JC, Kaplin A.
    Mult Scler; 2012 Feb 01; 18(2):202-9. PubMed ID: 21865410
    [Abstract] [Full Text] [Related]

  • 40. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B, REGARD study group.
    Lancet Neurol; 2008 Oct 01; 7(10):903-14. PubMed ID: 18789766
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.